Ownership and insider activity for Contineum Therapeutics, Inc. (CTNM): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Price
| Price | $13.76 |
| Market Cap | $518M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-08 | Stengone Carmine N. | M-Exempt | 2,500 | $3K |
| 2026-09-08 | Stengone Carmine N. | M-Exempt | 2,500 | $3K |
| 2026-09-08 | Stengone Carmine N. | S-Sale | 2,500 | $41K |
| 2026-08-03 | Stengone Carmine N. | M-Exempt | 2,500 | $3K |
| 2026-08-03 | Stengone Carmine N. | M-Exempt | 2,500 | $3K |
| 2026-08-03 | Stengone Carmine N. | S-Sale | 2,500 | $40K |
| 2026-07-08 | Lorrain Daniel S. | M-Exempt | 1,015 | $1K |
| 2026-07-09 | Lorrain Daniel S. | M-Exempt | 25 | $25 |
| 2026-07-09 | Lorrain Daniel S. | S-Sale | 25 | $400 |
| 2026-07-08 | Lorrain Daniel S. | M-Exempt | 1,015 | $1K |
Balance Sheet (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4.6M | $5.6M | $15.5M | $21.9M | $75.6M |
| Short-term Investments | $64.4M | $41.7M | $109.7M | $182.8M | $187.3M |
| Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $69.8M | $48.4M | $127.7M | $206.4M | $267.9M |
| Property, Plant & Equipment | $642000 | $2.1M | $1.4M | $6.5M | $8.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $70.5M | $50.6M | $130.4M | $212.8M | $276.6M |
| Accounts Payable | $660000 | $430000 | $635000 | $1.8M | $1.0M |
| Short-term Debt | $1.2M | $3.9M | 0 | 0 | 0 |
| Total Current Liabilities | $3.7M | $7.5M | $5.5M | $10.0M | $9.7M |
| Long-term Debt | $3.7M | 0 | $192.6M | 0 | 0 |
| Total Liabilities | $8.9M | $11.4M | $198.3M | $14.8M | $15.7M |
| Retained Earnings | -$73.6M | -$97.9M | -$75.1M | -$117.4M | -$177.4M |
| Total Equity | $61.6M | $39.3M | -$67.9M | $198.1M | $261.0M |
| Total Debt | $4.9M | $5.8M | $193.2M | $6.3M | $8.2M |
| Net Debt | -$64.1M | -$41.4M | $68.0M | -$198.5M | -$254.6M |
| Working Capital | $66.1M | $40.8M | $122.2M | $196.4M | $258.2M |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 37.17 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 11.55 |
Profitability
| Return on Equity | -24.73% |
| Return on Invested Capital | -26.96% |
| Return on Assets | -22.99% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACIU · ALDX · AMRN · ANRO · CADL · CAPR · KYTX
Explore sector: Healthcare · Biotechnology
More sections of CTNM: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks